Kathleen Mcelhone

Haslingden Road
Blackburn, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohort.

Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohort.

Journal: Clinical and experimental dermatology

Published: February 08, 2025

Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).

Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).

Journal: Clinical and experimental dermatology

Published: July 20, 2024

Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR.

Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: January 31, 2021

Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies.

Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: January 31, 2021

Flares in patients with systemic lupus erythematosus.

Flares in patients with systemic lupus erythematosus.

Journal: Rheumatology (Oxford, England)

Published: January 28, 2020

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 29, 2019

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.

Journal: The British journal of dermatology

Published: February 28, 2019

Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review.

Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review.

Journal: The British journal of dermatology

Published: January 06, 2019

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Journal: The British journal of dermatology

Published: June 13, 2018

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.

Journal: JAMA dermatology

Published: March 29, 2018

Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.

Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: June 26, 2017

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Journal: The Journal of investigative dermatology

Published: April 14, 2017

Showing 1-12 of 22

Last Updated: 09/26/2026